Development and Validation of RP-HPLC Method for Quantitative Estimation of Vinpocetine in Pure and Pharmaceutical Dosage Forms

A simple, precise, specific, and accurate reversed phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for determination of vinpocetine in pure and pharmaceutical dosage forms. The different analytical performance parameters such as linearity, accuracy, specificity, precision, and sensitivity (limit of detection and limit of quantitation) were determined according to International Conference on Harmonization ICH Q2 (R1) guidelines. RP-HPLC was conducted on Zorbax C18 (150 mm length × 4.6 mm ID, 5 μm) column. The mobile phase was consisting of buffer (containing 1.54% w/v ammonium acetate solution) and acetonitrile in the ratio (40 : 60, v/v), and the flow rate was maintained at 1.0 mLmin−1. Vinpocetine was monitored using Agilent 1200 series equipped with photo diode array detector (λ = 280 nm). Linearity was observed in concentration range of 160–240 μgmL−1, and correlation coefficient was found excellent (R2 = 0.999). All the system suitability parameters were found within the range. The proposed method is rapid, cost-effective and can be used as a quality-control tool for routine quantitative analysis of vinpocetine in pure and pharmaceutical dosage forms.

[1]  P. Whitehouse,et al.  Vinpocetine for cognitive impairment and dementia. , 2003, The Cochrane database of systematic reviews.

[2]  Toru Aizawa,et al.  Vinpocetine inhibits NF-κB–dependent inflammation via an IKK-dependent but PDE-independent mechanism , 2010, Proceedings of the National Academy of Sciences.

[3]  L. Vereczkey,et al.  Study on the absorption of vinpocetine and apovincaminic acid , 1993, European Journal of Drug Metabolism and Pharmacokinetics.

[4]  A. Medina,et al.  Vinpocetine as a potent antiinflammatory agent , 2010, Proceedings of the National Academy of Sciences.

[5]  M. Mesbah,et al.  Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products. , 2005, Farmaco.

[6]  E. Galván,et al.  Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes , 2005, Neurochemistry International.

[7]  D. Bereczki,et al.  A systematic review of vinpocetine therapy in acute ischaemic stroke , 1999, European Journal of Clinical Pharmacology.

[8]  L. Vereczkey,et al.  In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. , 2001, Polish journal of pharmacology.